TY - JOUR
T1 - Measurement precision across cognitive domains in the Alzheimer's Disease Neuroimaging Initiative (ADNI) data set
AU - Crane, Paul K.
AU - Choi, Seo-Eun
AU - Lee, Michael
AU - Scollard, Phoebe
AU - Sanders, R. Elizabeth
AU - Klinedinst, Brandon
AU - Nakano, Connie
AU - Trittschuh, Emily H.
AU - Mez, Jesse
AU - Saykin, Andrew J.
AU - Gibbons, Laura E.
AU - Wang, Chun
AU - Mungas, Dan
AU - Zhu, Ruoyi
AU - Foldi, Nancy S.
AU - Lamar, Melissa
AU - Jutten, Roos
AU - Sikkes, Sietske A. M.
AU - Grandoit, Evan
AU - Rabin, Laura A.
AU - Jones, Richard N.
AU - Tommet, Doug
AU - Mukherjee, Shubhabrata
N1 - Funding Information: Data collection and sharing for this project were funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI; National Institutes of Health Grant U01 AG024904) and Department of Defense ADNI (Award Number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; Bio-Clinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F.Hoffmann-La Roche Ltd and its affiliated companyGenentech, Inc.; Fujirebio; GE HealthCare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (https://www.fnih.org/). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The authors received funding from Grants U24 AG074855, U01 AG068057, U01 AG0006781, and R01 AG029672 (PI: Paul K. Crane); K25 AG055620 (PI: Shubhabrata Mukherjee); R01 AG061028 (PI: Jesse Mez); U19 AG066567 (MPI: E. Larson, Paul K. Crane, A. Lacroix); P30 AG066509 (PI: T. Grabowski); U01 AG042904, P30 AG010133, and R01 AG019771 (PI: Andrew J. Saykin); R01AG073439, R01 AG15819, R01AG17917, RF1 AG22018, and U01AG006781 (MPI: E. Larson, Paul K. Crane); SC3GM122662 (PI: Nancy S. Foldi); and R15AG066039 (PI: Laura A. Rabin) from the National Institute on Aging. The authors have no conflicts of interest to disclose. Publisher Copyright: © 2023 American Psychological Association
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Objective: To demonstrate measurement precision of cognitive domains in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) data set. Method: Participants with normal cognition (NC), mild cognitive impairment (MCI), and Alzheimer’s disease (AD) were included from all ADNI waves. We used data from each person’s last study visit to calibrate scores for memory, executive function, language, and visuospatial functioning. We extracted item information functions for each domain and used these to calculate standard errors of measurement. We derived scores for each domain for each diagnostic group and plotted standard errors of measurement for the observed range of scores. Results: Across all waves, there were 961 people with NC, 825 people with MCI, and 694 people with AD at their most recent study visit (data pulled February 25, 2019). Across ADNI’s battery there were 34 memory items, 18 executive function items, 20 language items, and seven visuospatial items. Scores for each domain were highest on average for people with NC, intermediate for people with MCI, and lowest for people with AD, with most scores across all groups in the range of −1 to +1. Standard error of measurement in the range from −1 to +1 was highest for memory, intermediate for language and executive functioning, and lowest for visuospatial. Conclusion: Modern psychometric approaches provide tools to help understand measurement precision of the scales used in studies. In ADNI, there are important differences in measurement precision across cognitive domains.
AB - Objective: To demonstrate measurement precision of cognitive domains in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) data set. Method: Participants with normal cognition (NC), mild cognitive impairment (MCI), and Alzheimer’s disease (AD) were included from all ADNI waves. We used data from each person’s last study visit to calibrate scores for memory, executive function, language, and visuospatial functioning. We extracted item information functions for each domain and used these to calculate standard errors of measurement. We derived scores for each domain for each diagnostic group and plotted standard errors of measurement for the observed range of scores. Results: Across all waves, there were 961 people with NC, 825 people with MCI, and 694 people with AD at their most recent study visit (data pulled February 25, 2019). Across ADNI’s battery there were 34 memory items, 18 executive function items, 20 language items, and seven visuospatial items. Scores for each domain were highest on average for people with NC, intermediate for people with MCI, and lowest for people with AD, with most scores across all groups in the range of −1 to +1. Standard error of measurement in the range from −1 to +1 was highest for memory, intermediate for language and executive functioning, and lowest for visuospatial. Conclusion: Modern psychometric approaches provide tools to help understand measurement precision of the scales used in studies. In ADNI, there are important differences in measurement precision across cognitive domains.
KW - cognition
KW - measurement precision
KW - psychometrics
UR - http://www.scopus.com/inward/record.url?scp=85159396626&partnerID=8YFLogxK
U2 - https://doi.org/10.1037/neu0000901
DO - https://doi.org/10.1037/neu0000901
M3 - Article
C2 - 37276134
SN - 0894-4105
VL - 37
SP - 373
EP - 382
JO - Neuropsychology
JF - Neuropsychology
IS - 4
ER -